{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=7",
    "query": {
      "condition": "Locally Advanced or Metastatic Breast Cancer",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 329,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Breast+Cancer&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T14:03:41.237Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03106415",
      "title": "Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Adenocarcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-09-27",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106415"
    },
    {
      "nct_id": "NCT03332797",
      "title": "A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "GDC-9545",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 181,
      "start_date": "2017-11-24",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332797"
    },
    {
      "nct_id": "NCT02776917",
      "title": "Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cirmtuzumab + Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Parker, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2018-08-15",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02776917"
    },
    {
      "nct_id": "NCT02115282",
      "title": "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Breast Adenocarcinoma",
        "HER2/Neu Negative",
        "Locally Advanced Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Recurrent Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 608,
      "start_date": "2014-03-29",
      "completion_date": "2027-06-02",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 652,
      "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Chico",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115282"
    },
    {
      "nct_id": "NCT06224673",
      "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2 Low Breast Carcinoma",
        "Triple Negative Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography (CT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Amiloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Laura Huppert, MD, BA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-06-05",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06224673"
    },
    {
      "nct_id": "NCT05113966",
      "title": "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan-hziy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-12-08",
      "completion_date": "2024-06-13",
      "has_results": true,
      "last_update_posted_date": "2025-01-29",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 22,
      "location_summary": "Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05113966"
    },
    {
      "nct_id": "NCT01281150",
      "title": "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Male Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-05-25",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 3,
      "location_summary": "Hershey, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01281150"
    },
    {
      "nct_id": "NCT04225117",
      "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "enfortumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2020-03-10",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225117"
    },
    {
      "nct_id": "NCT06799065",
      "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Breast Cancer Recurrent",
        "Ovarian Cancer",
        "High-grade Serous Ovarian Carcinoma",
        "Triple Negative Breast Cancer",
        "sqNSCLC",
        "Squamous Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ATX-295",
          "type": "DRUG"
        },
        {
          "name": "ATX-295 and bevacizumab (or biosimilar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Accent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2025-03-21",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06799065"
    },
    {
      "nct_id": "NCT05716516",
      "title": "STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2023-05-04",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-11T14:03:41.237Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05716516"
    }
  ]
}